Cargando...
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis have changed the first‐line treatment of people with advanced non‐small cell lung cancer (NSCLC). Single‐agent pembrolizumab (a PD‐1 inhibitor) is currently the standard of care as monotherapy in patients with PD‐L1 expres...
Gardado en:
| Publicado en: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley & Sons, Ltd
2021
|
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8092423/ https://ncbi.nlm.nih.gov/pubmed/33930176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013257.pub3 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|